Monopar Therapeutics SEC filings MNPR
Monopar Therapeutics has 536 filings in SEC EDGAR's recent list, going back to Jun 18, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 9, 2025 | — |
| CORRESP | Letter to the SEC | Sep 5, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2025 | — |
| CORRESP | Letter to the SEC | Jul 22, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| EFFECT | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2025 | — |
| EFFECT | Filing | Dec 17, 2024 | — |
| EFFECT | Filing | Jan 4, 2023 | — |
| CORRESP | Letter to the SEC | Dec 29, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2022 | — |
| EFFECT | Filing | Jan 13, 2020 | — |
| CORRESP | Letter to the SEC | Jan 10, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2020 | — |
| EFFECT | Filing | Dec 18, 2019 | — |
| CORRESP | Letter to the SEC | Dec 17, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Nov 7, 2019 | — |
| CORRESP | Letter to the SEC | Nov 6, 2019 | — |
| CORRESP | Letter to the SEC | Nov 5, 2019 | — |
| CERT | Filing | Oct 2, 2019 | — |
| CORRESP | Letter to the SEC | Oct 2, 2019 | — |
| CORRESP | Letter to the SEC | Oct 2, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| 8-A12B | Primary document | Sep 30, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2018 | — |
| CORRESP | Letter to the SEC | Dec 11, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2018 | — |
| CT ORDER | Filing | Jan 9, 2018 | — |
| 10-12G/A | Primary document | Jan 8, 2018 | — |
| 10-12G/A | Monopar therapeutics inc. form 10/a | Dec 20, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2017 | — |
| 10-12G | Monopar therapeutics inc. | Nov 9, 2017 | — |
| D | Filing | Aug 23, 2017 | — |
| D | Filing | Mar 28, 2017 | — |
| D | Filing | Mar 15, 2016 | — |
| D | Filing | Jun 18, 2015 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmette, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645469
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.